Assessing Nuvation Bio (NUVB) Valuation Following Phase 3 Safusidenib Trial Milestone

Simply Wall St.

10/25

Nuvation Bio (NUVB) just enrolled the first patient in its pivotal Phase 3 trial of safusidenib, a study designed to support regulatory approval for treating high-grade IDH1-mutant astrocytoma. This ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2578502999"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578502999\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578502999?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-10-25 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578502999","market":"hk","top_or_hot":-1,"title":"Assessing Nuvation Bio (NUVB) Valuation Following Phase 3 Safusidenib Trial Milestone","media":"Simply Wall St.","content":"<div>\n<p>Nuvation Bio (NUVB) just enrolled the first patient in its pivotal Phase 3 trial of safusidenib, a study designed to support regulatory approval for treating high-grade IDH1-mutant astrocytoma. This ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-following-phase-3-safu\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Nuvation Bio (NUVB) Valuation Following Phase 3 Safusidenib Trial Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Nuvation Bio (NUVB) Valuation Following Phase 3 Safusidenib Trial Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-25 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-following-phase-3-safu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nuvation Bio (NUVB) just enrolled the first patient in its pivotal Phase 3 trial of safusidenib, a study designed to support regulatory approval for treating high-grade IDH1-mutant astrocytoma. This ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-following-phase-3-safu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-following-phase-3-safu","article_id":"2578502999","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nuvb/nuvation-bio/news/assessing-nuvation-bio-nuvb-valuation-following-phase-3-safu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2578502999","pubTimestamp":1761405556,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Nuvation Bio (NUVB) just enrolled the first patient in its pivotal Phase 3 trial of safusidenib, a study designed to support regulatory approval for treating high-grade IDH1-mutant astrocytoma. This marks meaningful progress in the company’s late-stage clinical ambitions.\nSee our latest analysis for Nuvation Bio.\nThis clinical milestone appears to have sparked increased investor enthusiasm, as reflected in Nuvation Bio’s 1-day share price return of 10.48% and a robust 42.23% gain over the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","NUVB":"Nuvation Bio, Inc."},"translate_title":"3期Safusidenib试验里程碑后评估Nuvation Bio(NUVB)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"NUVB":1.5},"content_text":"Nuvation Bio (NUVB) just enrolled the first patient in its pivotal Phase 3 trial of safusidenib, a study designed to support regulatory approval for treating high-grade IDH1-mutant astrocytoma. This marks meaningful progress in the company’s late-stage clinical ambitions. See our latest analysis for Nuvation Bio. This clinical milestone appears to have sparked increased investor enthusiasm, as reflected in Nuvation Bio’s 1-day share price return of 10.48% and a robust 42.23% gain over the past week. Momentum has been building throughout the year, with total shareholder return reaching 119.46% in the past twelve months. This suggests that confidence in the company’s long-term outlook is on the rise. If promising biotech trials make you consider broader innovation, you may want to explore fresh opportunities with our See the full list for free. With shares surging and clinical milestones in hand, is Nuvation Bio still undervalued after its standout gains? Or are investors already pricing in the company’s future breakthroughs and growth?\nAdvertisementPrice-to-Book of 4.5x: Is it justified? Compared to its last closing price of $4.85, Nuvation Bio’s price-to-book ratio (4.5x) stands out when stacked alongside both peers and industry norms. This multiple suggests a noteworthy premium in how the market currently values the company's net assets. The price-to-book ratio measures what investors are willing to pay today for each dollar of a company’s net assets. For biotech companies like Nuvation Bio, which often operate in asset-light, high-risk environments, this metric can signal whether the company’s growth potential is seen as justifying a higher valuation over underlying book value. Nuvation Bio’s ratio is well below the average of its peer group (11.5x), implying that investors may see more value relative to those companies. However, it appears expensive when compared to the broader US Pharmaceuticals industry average of 2.2x, suggesting that some future potential might already be factored in. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 4.5x (ABOUT RIGHT) However, uncertainty remains around ongoing clinical results and Nuvation Bio’s ability to translate pipeline progress into sustained revenue growth in a competitive sector. Find out about the key risks to this Nuvation Bio narrative. Another View: Discounted Cash Flow Suggests Deeper Value Looking through the lens of our DCF model, Nuvation Bio’s current share price of $4.85 sits significantly below our estimate of fair value, which lands at $19.47. This suggests that, despite recent price appreciation, there could still be substantial upside the market has yet to recognize. Look into how the SWS DCF model arrives at its fair value. NUVB Discounted Cash Flow as at Oct 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nuvation Bio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Nuvation Bio Narrative If you have your own perspective or want to dig deeper into Nuvation Bio’s numbers, you can quickly piece together a narrative of your own in just a few minutes. Do it your way A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Don’t let great opportunities pass you by. Expand your watchlist with handpicked stocks that match your strategy using tailored screeners built for smart investors.  Maximize your potential returns by reviewing these 877 undervalued stocks based on cash flows, which may be trading below their true worth and could give you an edge on the market. Step up your passive income strategy by checking out these 17 dividend stocks with yields > 3% that offer strong yields for long-term growth and stability. Ride the AI innovation wave by spotting these 27 AI penny stocks that are set to benefit most from the artificial intelligence revolution and breakthrough advancements.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}